Abstract
Patients on a statin regimen have a decreased risk of death due to bacterial sepsis. We have found that protection by simvastatin includes the inhibition of host cell invasion by Staphylococcus aureus, the most common etiologic agent of sepsis. Inhibition was due in part to depletion of isoprenoid intermediates within the cholesterol biosynthesis pathway and led to the cytosolic accumulation of the small GTPases CDC42, Rac, and RhoB. Actin stress fiber disassembly required for host invasion was attenuated by simvastatin and by the inhibition of phosphoinositide 3-kinase (PI3K) activity. PI3K relies on coupling to prenylated proteins, such as this subset of small GTPases, for access to membrane-bound phosphoinositide to mediate stress fiber disassembly. Therefore, we examined whether simvastatin restricts PI3K cellular localization. In response to simvastatin, the PI3K isoform p85, coupled to these small-GTPases, was sequestered within the cytosol. From these findings, we propose a mechanism whereby simvastatin restricts p85 localization, inhibiting the actin dynamics required for bacterial endocytosis. This approach may provide the basis for protection at the level of the host in invasive infections by S. aureus.
Footnotes
-
This work was funded by the National Institutes of Health Grant R15 HL079971-01 and by the National Science Foundation Louis Stokes Alliance for Minority Participation Grant 0217615.
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.108.137927.
-
ABBREVIATIONS: MRSA, methicillin-resistant S. aureus; GGpp, geranylgeranyl pyrophosphate; Fpp, farnesyl pyrophosphate; PI3K, phosphoinositide 3-kinase; GAP, GTPase-activating protein; LY294002, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; PBS, phosphate-buffered saline; DMSO, dimethyl sulfoxide; HUVEC, human umbilical vein endothelial cells; FBS, fetal bovine serum; HEK, human embryonic kidney; ANOVA, analysis of variance; GGOH, dephosphorylated form of GGpp; PAGE, polyacrylamide gel electrophoresis; GGTI-2147, 4-{[N-(imidazol-4-yl)methyleneamino]-2-(1-naphthyl)benzoyl}leucine methyl ester; FTI-277, methyl {N-[2-phenyl-4-N[2(R)-amino-3-mercaptopropylamino]benzoyl]}-methionate.
- Received February 13, 2008.
- Accepted April 2, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|